抗逆转录病毒蛋白酶抑制剂沙奎那韦和利托那韦与氯喹和甲氟喹在体外对恶性疟原虫的协同相互作用。
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
作者信息
Skinner-Adams T S, Andrews K T, Melville L, McCarthy J, Gardiner D L
机构信息
University of Queensland, Department of Medicine, Brisbane, Australia.
出版信息
Antimicrob Agents Chemother. 2007 Feb;51(2):759-62. doi: 10.1128/AAC.00840-06. Epub 2006 Nov 6.
Abstract
The antimalarial activity of several antiretroviral protease inhibitor combinations was investigated. Data demonstrate that ritonavir and saquinavir behave synergistically with chloroquine and mefloquine. These data, and interactions with pepstatin-A, E-64, and bestatin, suggest that human immunodeficiency virus protease inhibitors do not target digestive-vacuole plasmepsins.
摘要
对几种抗逆转录病毒蛋白酶抑制剂组合的抗疟活性进行了研究。数据表明，利托那韦和沙奎那韦与氯喹和甲氟喹具有协同作用。这些数据以及与胃蛋白酶抑制剂A、E-64和氨肽酶抑制剂的相互作用表明，人类免疫缺陷病毒蛋白酶抑制剂并非以消化液泡中的疟原虫天冬氨酸蛋白酶为作用靶点。
相似文献
1
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.抗逆转录病毒蛋白酶抑制剂沙奎那韦和利托那韦与氯喹和甲氟喹在体外对恶性疟原虫的协同相互作用。
Antimicrob Agents Chemother. 2007 Feb;51(2):759-62. doi: 10.1128/AAC.00840-06. Epub 2006 Nov 6.
2
Antiretrovirals as antimalarial agents.抗逆转录病毒药物作为抗疟剂。
J Infect Dis. 2004 Dec 1;190(11):1998-2000. doi: 10.1086/425584. Epub 2004 Nov 3.
3
Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.抗逆转录病毒蛋白酶抑制剂通过调节细胞内谷胱甘肽代谢增强疟原虫对氯喹的抗疟活性。
Exp Parasitol. 2009 Oct;123(2):122-7. doi: 10.1016/j.exppara.2009.06.008. Epub 2009 Jun 16.
4
Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.沙奎那韦抑制疟原虫的氯喹耐药转运蛋白。
Antimicrob Agents Chemother. 2012 May;56(5):2283-9. doi: 10.1128/AAC.00166-12. Epub 2012 Feb 21.
5
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.1型人类免疫缺陷病毒蛋白酶抑制剂对间日疟原虫临床分离株的活性强于对恶性疟原虫临床分离株的活性。
Antimicrob Agents Chemother. 2008 Jul;52(7):2435-41. doi: 10.1128/AAC.00169-08. Epub 2008 Apr 28.
6
Declining chloroquine resistance of Plasmodium falciparum in Lambaréné, Gabon from 1992 to 1998.1992年至1998年加蓬兰巴雷内恶性疟原虫对氯喹耐药性的下降情况
Wien Klin Wochenschr. 2001 Jan 15;113(1-2):63-4.
7
Antimalarial activity of sera from subjects taking HIV protease inhibitors.服用HIV蛋白酶抑制剂的受试者血清的抗疟活性。
AIDS. 2007 Mar 30;21(6):763-5. doi: 10.1097/QAD.0b013e328031f41a.
8
Roxithromycin potentiates the effects of chloroquine and mefloquine on multidrug-resistant Plasmodium falciparum in vitro.罗红霉素可增强氯喹和甲氟喹在体外对多重耐药恶性疟原虫的作用。
Exp Parasitol. 2007 Apr;115(4):387-92. doi: 10.1016/j.exppara.2006.10.004. Epub 2006 Nov 21.
9
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.人类免疫缺陷病毒蛋白酶抑制剂在体外对恶性疟原虫的效力以及在体内对鼠疟的效力。
Antimicrob Agents Chemother. 2006 Feb;50(2):639-48. doi: 10.1128/AAC.50.2.639-648.2006.
10
In-vitro sensitivity of Plasmodium falciparum to chloroquine, halofantrine, mefloquine and quinine in Madagascar.马达加斯加恶性疟原虫对氯喹、卤泛群、甲氟喹和奎宁的体外敏感性
East Afr Med J. 2002 May;79(5):237-41.
引用本文的文献
1
A Review on Synthetic Thiazole Derivatives as an Antimalarial Agent.合成噻唑衍生物作为抗疟药物的综述。
Curr Drug Discov Technol. 2024;21(5):e240124226141. doi: 10.2174/0115701638276379231223101625.
2
A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.针对疟原虫天冬氨酸蛋白酶IX/X作为疟疾治疗靶点的潜在毒理学风险的目标安全性评估。
Toxicol Res (Camb). 2021 Feb 15;10(2):203-213. doi: 10.1093/toxres/tfaa106. eCollection 2021 Mar.
3
Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Genotype.基因型对基于青蒿素的三联联合疗法药效学的调节作用
ACS Pharmacol Transl Sci. 2020 Nov 2;3(6):1144-1157. doi: 10.1021/acsptsci.0c00110. eCollection 2020 Dec 11.
4
The Impact of Antiretroviral Therapy on Malaria Parasite Transmission.抗逆转录病毒疗法对疟原虫传播的影响。
Front Microbiol. 2020 Jan 24;10:3048. doi: 10.3389/fmicb.2019.03048. eCollection 2019.
5
Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone.环化受阻的伯氨喹作为提高阿托伐醌抗疟活性的策略。
Commun Biol. 2019 May 3;2:166. doi: 10.1038/s42003-019-0397-3. eCollection 2019.
6
Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.临床批准的组蛋白去乙酰化酶抑制剂对疟原虫、利什曼原虫和血吸虫寄生虫生长的影响。
Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):42-50. doi: 10.1016/j.ijpddr.2016.12.005. Epub 2016 Dec 23.
7
Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei.来自啮齿动物疟原虫伯氏疟原虫的重组食物泡组织蛋白酶4的酶学特性分析
PLoS One. 2015 Oct 28;10(10):e0141758. doi: 10.1371/journal.pone.0141758. eCollection 2015.
8
Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.青蒿琥酯-甲氟喹与利托那韦增强型洛匹那韦在泰国健康成年人中的药代动力学相互作用。
Malar J. 2015 Oct 9;14:400. doi: 10.1186/s12936-015-0916-8.
9
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.羟氯喹和氯喹在治疗系统性红斑狼疮、类风湿关节炎及相关疾病中的治疗和药理学特性。
Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6.
10
Total synthesis of thiaplakortone a: derivatives as metabolically stable leads for the treatment of malaria.硫代普拉可酮A的全合成：作为治疗疟疾的代谢稳定先导化合物的衍生物
ACS Med Chem Lett. 2013 Dec 27;5(2):178-82. doi: 10.1021/ml400447v. eCollection 2014 Feb 13.
本文引用的文献
1
Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.1型人类免疫缺陷病毒蛋白酶抑制剂的抗疟作用与天冬氨酸蛋白酶抑制剂胃蛋白酶抑制剂不同。
Antimicrob Agents Chemother. 2006 Jun;50(6):2207-9. doi: 10.1128/AAC.00022-06.
2
Nucleus may be the key site of chloroquine antimalarial action and resistance development.细胞核可能是氯喹抗疟作用及耐药性产生的关键部位。
Med Hypotheses. 2006;67(2):323-6. doi: 10.1016/j.mehy.2006.02.008. Epub 2006 Mar 23.
3
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.人类免疫缺陷病毒蛋白酶抑制剂在体外对恶性疟原虫的效力以及在体内对鼠疟的效力。
Antimicrob Agents Chemother. 2006 Feb;50(2):639-48. doi: 10.1128/AAC.50.2.639-648.2006.
4
Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin.恶性疟原虫中亮氨酰氨肽酶的过表达。贝司他汀抗疟活性的靶点。
J Biol Chem. 2006 Jan 20;281(3):1741-5. doi: 10.1074/jbc.M508955200. Epub 2005 Nov 14.
5
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.1型人类免疫缺陷病毒蛋白酶抑制剂的抗疟活性。
Antimicrob Agents Chemother. 2005 Jul;49(7):2983-5. doi: 10.1128/AAC.49.7.2983-2985.2005.
6
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.与甲氟喹共同给药时，沙奎那韦的体外协同作用及增强的小鼠脑内渗透作用。
J Pharmacol Exp Ther. 2005 Sep;314(3):1202-9. doi: 10.1124/jpet.105.086272. Epub 2005 May 27.
7
Contribution of the pfmdr1 gene to antimalarial drug-resistance.pfmdr1基因对疟疾耐药性的作用。
Acta Trop. 2005 Jun;94(3):181-90. doi: 10.1016/j.actatropica.2005.04.008.
8
Therapeutic drugs for targeting chloroquine resistance in malaria.针对疟疾氯喹抗性的治疗药物。
Mini Rev Med Chem. 2005 Apr;5(4):337-51. doi: 10.2174/1389557053544029.
9
Antiretrovirals as antimalarial agents.抗逆转录病毒药物作为抗疟剂。
J Infect Dis. 2004 Dec 1;190(11):1998-2000. doi: 10.1086/425584. Epub 2004 Nov 3.
10
The role of Plasmodium falciparum food vacuole plasmepsins.恶性疟原虫食物泡天冬氨酸蛋白酶的作用。
J Biol Chem. 2005 Jan 14;280(2):1432-7. doi: 10.1074/jbc.M409740200. Epub 2004 Oct 28.
Zotero 插件